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Central Airway Toxicity After High Dose Radiation: A Combined Analysis of Prospective 
Clinical Trials for Non-Small Cell Lung Cancer  
ABSTRACT 
Purpose: To study the dosimetric risk factors for radiation-induced proximal bronchial tree (PBT) 
toxicity in patients treated with radiotherapy for non-small cell lung cancer (NSCLC).  
Methods and Materials: Patients with medically inoperable/unresectable NSCLC treated with 
conventionally fractionated 3D conformal radiotherapy (3DCRT) in prospective clinical trials 
were eligible for this study. PBT and PBT wall (PBTW) were contoured consistently per RTOG
1106 OAR-Atlas. The dose-volume histograms (DVHs) of physical prescription dose (DVHp) 
and biological effective dose (α/β=2.5, DVH2.5) were generated respectively. The primary 
endpoint was PBT toxicities, defined by CTCAE 4.0 under the terminology of bronchial 
stricture/atelectasis. 
Results: Of a total of 100 patients enrolled, with a median follow-up of 64 (95% CI, 50-78) 
months, 73% received 70 Gy or above, and 17% developed PBT toxicity (Grade 1, 8%; Grade 2, 
6%; Grade 3, 0% and Grade 4, 3%). The median time interval between RT initiation and onset of 
PBT toxicity was 8.4 (95% CI, 4.7-44.1) months. The combined DVHs showed that no patient 
with a PBT maximum physical dose <65 Gy developed any PBT toxicity. Cox proportional 
hazards analysis and receiver operating characteristic analysis demonstrated that V75 of PBT 
was the most significant dosimetric parameter for both Grade 1+ (P=0.035) and Grade 2+ 
(P=0.037) PBT toxicities. The dosimetric thresholds for V75 of PBT were 6.8% and 11.9% for 
Grade 1+ and Grade 2+ PBT toxicity, respectively.  
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Conclusions: V75 of PBT appeared be the most significant dosimetric parameter for PBT 
toxicity after conventionally fractionated thoracic 3DCRT. Constraining V75 of PBT may limit 




Lung cancer, predominantly non-small cell lung cancer (NSCLC), is the leading cause of 
cancer-related death worldwide, and radiotherapy (RT) plays a major role in lung cancer 
treatment.1,2 For locally advanced NSCLC, conventionally fractionated 3-dimensional conformal 
RT (3DCRT) with or without concurrent chemotherapy is the standard of care.3,4 For early stage 
NSCLC, stereotactic body radiation therapy (SBRT) has become the treatment of choice for 
medically inoperable peripheral disease, with excellent local control and low toxicity,5 but 
conventional 3DCRT remains a viable modality for high-risk centrally-located tumors owing to 
the risk of toxicity of SBRT to central organs. Higher doses of 3DCRT may improve 
local/regional tumor control; however, it is accompanied by the increased risk of RT-induced 
toxicities in thoracic organs at risk (OARs).3,6 Among these OARs toxicities, radiation-induced 
central airway toxicity, i.e. proximal bronchial tree (PBT) damage, is a concerning long-term 
toxicity issue.  
Acute bronchitis during thoracic RT usually presents as slight or mild respiratory symptoms, 
while long-term radiation-induced damage of bronchi can lead to bronchial fibrosis, stenosis, and 
partial or complete lung collapse.7 RT-induced PBT toxicity can be clinically unnoticeable, 
severe, or even life-threatening, depending on the extent of damage and patient-specific issues, 
including pulmonary function and general performance status. However, due to the lower rate of 
incidence and longer emerging period, studies on PBT toxicity in conventional thoracic 3DCRT 
are limited and the safe dose constraints to central airway remain unknown.8 To guide RT 
treatment planning in clinical practice and to minimize severe long-term central airway toxicities, 
evidence on radiation dose-tolerance to PBT is needed. 
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The aim of the present study was to assess the relationship between dosimetric parameters and 
PBT toxicities with consideration of clinical factors. We hypothesized that clinical or 
dose-volume histogram (DVH) parameters can predict radiation-induced PBT toxicity. 
Specifically, this study aimed to investigate whether: 1) clinical factors and/or dosimetric 
parameters from DVHs of PBT or PBT wall (PBTW) can predict PBT toxicity; and 2) dosimetric 
constraints of PBT can be identified to limit clinically significant toxicities. 
 
METHODS AND MATERIALS  
Patients’ characteristics 
This study included patients with stage I-III NSCLC enrolled in prospective clinical trials 
approved by institutional review boards (IRBs). Written informed consent was obtained from all 
patients. Eligible patients received definitive thoracic 3DCRT with or without concurrent 
chemotherapy with a total prescription dose at least 60 Gy and had computed tomography (CT) 
scans, treatment plans, volumes of interest, and dose distributions available for this analysis. 
Details of these prospective clinical trials were summarized in supplementary Table S1. 
Radiation treatment 
CT scans were acquired in the treatment position with patients immobilized in the supine 
position with arms above their heads. Scan covered the entire thorax, with a minimum of 3-mm 
slice thickness. Simulation CT scans of the chest were performed either under natural breath, 
three phases with breath held at the end of voluntary inhale, at the end of voluntary exhale, and 
while breathing freely, or under multiple phases of 4D scans. When 4D-CT was used, average 
scans were applied for PBT/PBTW contouring. When three phase scans were performed, scans at 
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the end of natural exhale were used, as it was considered to be the most representative scan since 
75% of the breathing time in human beings is during exhalation. Intravenous contrast was 
applied in most of the patients for target delineation. Radiotherapy was delivered using a 3D 
conformal technique. A total dose of 60-85.5 Gy was delivered with daily fractions of 1.8-3.8 Gy 
given over 6-7 weeks using 6 or 16 MV photons. Equivalent doses in 2 Gy fractions (EQD2) for 
the total dose were computed for those received doses other than 2 Gy daily, using an alpha/beta 
ratio of 10. Gross tumor volume (GTV) was contoured and edited according to the treating 
radiation oncologist. The total dose delivered to the planning target volume (PTV) was adjusted 
when necessary based on the tolerance of critical organs at risk (OARs): the normal lung was 
limited to a mean dose of <20 Gy or the normal tissue complication probability (NTCP) for lung 
less than 17-20%; maximum spinal cord dose <50 Gy; maximum brachial plexus dose <66 Gy; 
the whole, 2/3, and 1/3 of heart received <40 Gy, <45 Gy and <60 Gy, respectively. Of note, no 
constraint to PBT was applied in these clinical trials. 
Dosimetric analyses of PBT and PBTW 
The PBT and PBTW were retrospectively contoured on each axial scan of the planning CT 
according to the atlas of RTOG 1106 recommendations 
(http://www.rtog.org/CoreLab/ContouringAtlases/LungAtlas.aspx).9 The contours were drawn by 
the first physician author and checked by the senior author. The PBT included the distal 2 cm of 
the trachea, the carina, the right and left mainstem bronchi, the right and left upper lobe bronchi, 
the bronchus intermedius, the right middle lobe bronchus, the lingular bronchus, and the right 
and left lower lobe bronchi. In the treatment planning system, the PBT was contoured by 
auto-segmenting the airspace of the central airway with 3 mm expansion to include the wall. The 
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PBTW was contoured by subtracting the airspace of the central airway from the PBT. The 
cumulative DVHs of physical dose (DVHp) of PBT and PBTW were generated from the 
summation of treatment plans. To consider the biological effect caused by different dose 
fractionation, the biological effective dose DVHs (DVH2.5) for PBT and PBTW were generated 
using the Linear Quadratic model with alpha/beta ratio of 2.5. Dosimetric parameters including 
mean dose, maximum point doses computed in 0.03 cc, 0.5 cc and 1.0 cc and volumes receiving 
doses greater than 5-100 Gy (V5-V100) were extracted from DVHp and DVH2.5, respectively. 
To evaluate the potential effect of primary tumor location on PBT toxicity, we graded the 
tumor-PBT relationship based on tumor location as following: Group I, the tumor is out of main 
bronchus; Group II, the tumor is within the main bronchus, but >2 cm from the carina; Group III, 
the tumor is within the main bronchus, and <2m from the carina but not involving it; Group IV, 
the tumor involves the tracheal carina.  
DVH atlas analysis 
As recommended by the Quantitative Analysis of Normal Tissue Effects in the Clinic 
(QUANTEC) group,10,11 DVH atlases were mapped for the risk of PBT toxicity using Microsoft 
Excel spreadsheet. Each cell within the atlas described a small range of dose and volume (5 Gy 
in dose and 10% in PBT volume). The number in percentage in each cell presents the percentile 
of patients with PBT toxicity within the patients whose DVH fell within the range of dose and 
volume of this cell. 
Follow-up and PBT toxicity evaluations 
Patients were followed in clinic and chest CT scans were performed at 3, 6, 9, 12, 18, and 24 
months after RT, and yearly thereafter. Additional CT or PET/CT scans were performed as 
  
 7
clinically indicated. Toxicity was assessed using the National Cancer Institute Common 
Terminology Criteria for adverse events (CTECAE) version 4.0 for bronchial stricture or 
atelectasis. Briefly, Grade 1: Asymptomatic, clinical or diagnostic observations only, intervention 
not indicated; Grade 2: symptomatic, general medicine/clinical procedure indicated; Grade 3: 
severe symptom, specialized/surgical intervention indicated; Grade 4: life-threatening respiratory 
or hemodynamic compromise; intubation or urgent intervention indicated; Grade 5: death.  
Statistical analysis 
The primary endpoint was PBT toxicity greater than or equal to grade 2 (Grade 2+); however, we 
also analyzed PBT toxicity greater than or equal to grade 1 (Grade 1+). The time frame for 
developing PBT toxicity was calculated from the beginning of thoracic RT to the date of reported 
PBT toxicity. Patients without PBT toxicity were censored at death or last follow-up. Cox 
proportional hazards model was used to assess the correlations between the variables (clinical 
factors and dosimetric parameters) and the PBT toxicity, by estimating the hazard ratios (HR) 
with 95% confidence interval (95% CI). Any variables with P<0.05 in univariate analysis were 
selected as co-variants for adjustment in multivariate analysis. The areas under the curve (AUC) 
of receiver operating characteristic (ROC) curves was used to quantify the ability of positive 
factors to discriminate patients who did versus did not develop PBT toxicity. Optimal cutoff 
values for statistically significant variables were determined by the maximum Youden index 
(sensitivity + specificity – 1) plus calculation of positive predict value (PPV) and negative 
predict value (NPV). Analyses were carried out using SPSS, version 22.0 (IBM, Armonk, NY) 





Patients’ characteristics and PBT toxicity 
A total of 106 patients were enrolled between 2004 to 2012 in prospective radiotherapy trials in 
which PBT toxicity data was recorded prospectively. Six patients were excluded due either to 
palliative dose (<60 Gy, n=4) or lost follow-up (off-study, n=2). All patients were treated with 
3DCRT. Eighty-three patients (83%) had stage III NSCLC; 88 patients (88%) received 
concurrent chemo-radiation therapy. A total of 17 patients (17%) developed PBT toxicity (8% 
Grade 1, 6% Grade 2, 0% Grade 3, and 3% Grade 4) at a median follow-up of 64 (95% CI, 50-78) 
months. The median time interval between treatment initiation and onset of PBT toxicity was 8.4 
(95% CI, 4.7-44.1) months. Univariate analysis showed that none of the clinical factors, 
including age, gender, smoking history, tumor location, tumor-PBT relationship, histology, 
clinical stage, Karnofsky performance status (KPS), chronic obstructive pulmonary disease 
(COPD), radiation dose (EQD2) and chemotherapy, correlated significantly with the risk of 
Grade 1+ or Grade 2+ PBT toxicity (all P-values>0.05). Specifically, the PBT toxicity had a 
trend of increase with the increase of grade of the tumor-PBT relationship, but did not reach 
statistical significance (Table 1). 
Of note, 3 patients (3%) developed Grade 4 PBT toxicity at 5.5, 14.0, and 14.5 months after 
thoracic RT. The three patients presented with symptoms including dyspnea, hypoxia, cough, or 
pneumonia due to bronchial stenosis. PBT damage was verified for these 3 patients by 
bronchoscopy with biopsy showing no evidence of tumor progression. F gure S1 showed a 
patient with post-RT distal tracheal stenosis and bronchomalacia/tracheomalacia had undergone 
tracheal stent placement for the complication.   
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Combined DVHs of PBT/PBTW for 100 patients 
Figure 1 shows combined DVHp of PBT (Figure 1A) and PBTW (Figure 1B) for all 100 
patients. Although distributions of DVHp were heterogeneous, the DVHp in patients with Grade 
2+ PBT toxicity (the red curves) tended to fall in the high dose region (V75~V100) compared to 
those patients without PBT toxicity (the blue curves). The combined DVHp of PBTW showed 
similar results, and so did the combined DVH2.5 for both PBT and PBTW (Figure S2). Because 
all patients with PBT toxicity had V65 ≥0, we selected V65-V100, together with mean doses and 
maximum point doses of PBT and PBTW, for further Cox proportional hazards analysis. 
DVH atlas for PBT 
Mapping DVH atlases for Grade 1+ (Figure 2A) Grade 2+ (Figure 2B) PBT toxicity 
demonstrated that areas of DVHs exhibiting higher rates of Grade 1+ or 2+ toxicity lay in the 
bottom right corner of the plots. In this area, the rates of Grade 1+ and Grade 2+ toxicity reached 
40%-75% and 20%-75% when 20%-50% of PBT volume received radiation doses of 70-90 Gy. 
Although at 45 Gy there was a small area exhibiting rates of 50% for 20% volume for both 
toxicity grades, the majority of high risk toxicity fell in the high dose region (70-90 Gy). 
DVH parameters for PBT/PBTW and PBT toxicity 
None of maximal point doses or mean doses from PBT/PBTW DVH correlated significantly 
with either Grade 1+ or Grade 2+ PBT toxicities (P>0.05). Cox proportional hazards analysis 
showed that several volumetric parameters from DVHp or DVH2.5 were significantly associated 
with PBT toxicity (Table 2). By ROC analysis, V80_PBTW (AUC=0.684) and V75_PBT 
(AUC=0.729) had the best capacity for predicting Grade 1 and Grade 2 PBT toxicity, 
respectively (Table 2, Figure 3A and 3B).   
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Predictive accuracy and cut-offs recommendation  
As it had a higher AUC for clinically significant PBT toxicity (Grade 2+) compared to that of 
other volumetric parameters, V75_PBT was selected as the dosimetric constraint to test 
predicting accuracy, such that an optimal cutoff for dose-limitation could be elucidated. To 
maximize the Youden index, the optimal cutoff points of V75 of PBT to predict toxicity were 6.8% 
for Grade 1 toxicity (sensitivity 65%, specificity 72%, PPV 32%, NPV 91%) and 11.9% for 
Grade 2 toxicity (sensitivity 78%, specificity 76%, PPV 24%, NPV 97%) (Figure 3C and 3D).  
Kaplan-Meier Log Rank test validated that the hazards of PBT toxicity were significantly 
decreased by limiting V75_PBT ≤ 6.8% for Grade 1 (32% vs. 9%, P = 0.026) and V75_PBT or ≤ 
11.9% Grade 2 (24% vs. 3%, P = 0.003), respectively. (Figure 4A and 4B)    
DISCUSSION 
This study demonstrates in patients treated with daily fractionated thoracic 3DCRT that: (1) high 
dose volumes rather than maximal point doses or tumor prescription doses (EQD2) were 
significantly correlated with radiation-induced central airway toxicity; (2) dosimetric parameters 
from PBT or PBT wall were comparable in their correlation with the toxicity; (3) none of the 
patients with PBT receiving less than 65 Gy physical dose developed any PBT toxicity; (4) V75 
of PBT was the most significant dosimetric parameter for Grade 2+ PBT toxicity, and dosimetric 
constraint of V75 of PBT ≤ 11.9% may be used to limit clinical significant Grade 2+ PBT 
toxicity. These results are the first in the human literature support our hypothesis that DVH 
parameters can predict radiation-induced PBT toxicity, and that PBT toxicity can be limited by 
limiting the volume to 75 Gy. 
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Radiation-induced central airway damage may be an underreported complication in lung cancer 
patients treated with thoracic RT, due to its mostly unnoticeable nature and to censoring by short 
post-treatment patient survival.8 PBT was not even listed as a critical structure in some 
3DCRT3,12 and intensity-modulated RT (IMRT)13 clinical trials although PBT adverse events did 
occur in these studies. Our findings that 9% had Grade 2+ toxicity after median RT dose 78.4 Gy 
(range, 66-85.5 Gy) at a median interval of onset of PBT toxicity of 8.4 months, with a wide 
range of 4.7-44.1 months, agree with and extend findings of Kelsey et al., who reported a 
narrowing of the mainstem bronchi as early as 3 months after thoracic RT.7 These numbers 
indicate that PBT toxicity is a typical late adverse event (defined as >3 months after treatment). 
Our data also showed that the incidence rates of Grade 1+ and Grade 2+ PBT toxicity were 17% 
and 9%, respectively. Most studies in the current literature reported sparse rates of late toxicity 
after conventional external beam thoracic RT.14,15 Miller et al. reported that bronchial stenosis 
reached 38% after 4 years follow up in 103 NSCLC patients treated with definitive thoracic RT 
with prescription doses of 70.8-74.5 Gy with unknown PBT dosimetry. The rate of PBT toxicity 
in that study appeared to be significantly higher than our study. The likely explanation is that, 
although the total prescription doses were similar to the current study, they used twice-daily 
fractionation.8 This disparity suggests that a more conservative dose constraint to PBT should be 
considered when using a non-conventional RT modality in treatment planning. The DVH 
parameters with the cutoffs we provide in this study should be considered to be references only 
for daily fractionated 3DCRT treatment planning. 
As there was no other comprehensive dosimetric study performed previously on PBT toxicity 
after 3DCRT, particularly like this one with clearly defined PBT OAR structure, this study may 
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be the first of its kind to appear in the literature. Current practice used maximal point doses in 
various volumes for PBT dose constraints, for clinical trials of SBRT,16,17 largely based on 
assumption of series organ in biological functions. However, our data support volumetric dose 
parameters as more important than maximum point dose parameters in predicting 
radiation-induced PBT toxicity after 3DCRT. Of note, by retrospectively analyzing 74 patients 
treated with SBRT, Karlsson et al. reported a significant dose-response relationship between the 
incidence of atelectasis and the maximal dose of the bronchi (defined by 0.1 cc).18 This 
difference in the dosimetric predictor for PBT toxicity - specifically, the difference between 
3DCRT and SBRT - suggests that hypofractionated radiation possesses different biologic effects 
on normal tissues, namely PBT.  
It is worth highlighting that parameters from biologically-corrected dose DVHs (DVH2.5) were 
not superior to those from physical dose DVHs in PBT toxicity prediction based on AUC values 
(Table 2) although we analyzed all important parameters from both DVHs. A likely explanation 
is that most patients received radiotherapy with conventional dose fractionations (2 Gy/fraction). 
In addition, parameters from DVHs of PBT wall (excluding air cavity) were also not 
significantly superior to those from DVHs of PBT in toxicity prediction. This finding suggests 
that including versus excluding the air in the bronchial lumen during PBT contouring planning 
has minor influence on the DVH calculation, the common way of contouring per RTOG1106 
trial is clinically reasonable.   
Interestingly, none of the clinical factors significantly correlated with any grade of PBT toxicity. 
Furthermore, no patients with a PBT maximum dose <65 Gy developed any grade of PBT 
toxicity in this study. Hence, development of clinically noticeable PBT damage requires that a 
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significant part of PBT volume be located in the high dose region (≥65 Gy). Thus, high 
dose-volume is the key factor for radiation-induced PBT toxicity, a finding further supported by 
the DVH atlas analysis. The high incidence of PBT toxicity region (>40%) mostly lay in the high 
dose area (70-90 Gy) with essential PBT volumes of 20%-50%. Most importantly, by comparing 
prediction accuracy, we found that V75 of PBT may be the most optimal dosimetric parameter 
for the prediction of PBT toxicity, a finding that will require independent validation. Furthermore, 
by maximizing Youden index, a commonly used method of threshold determination, we 
identified the optimal cutoff values for V75 of PBT (<11.9%) to predict Grade 2+ PBT toxicity.  
We recognize that this study is limited in several aspects. Firstly, a sample size of 100 is small 
with a limited number of PBT toxicity events (especially for Grade 2+ 9% only), which may 
have underpowered the significance of testing in clinical variables. Secondly, similar to other 
OARs, chemotherapy could affect the rate and severity of PBT toxicity. This study was not 
powered to detect the effect of chemotherapy on PBT toxicity, as only 12 of our 100 patients did 
not receive chemotherapy, nor was it the primary aim of the current study. Rather, this study will 
be the first of its kind to perform comprehensive dosimetric modeling for PBT. Nonetheless, 
additional validation studies with larger sample sizes are desired to increase the clinical 
significance of the data. 
CONCLUSIONS 
This study demonstrates that the PBT volumes receiving high dose may be more important than 
the traditionally believed maximal point dose parameters to predict radiation-induced central 
airway toxicity following 3DCRT. Patients with PBT receiving dose less than 65 Gy have 
minimal risk of developing PBT toxicity after thoracic 3DCRT. V75 of PBT may be the most 
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predictive dosimetric parameter in predicting clinically significant PBT toxicity in thoracic 
radiotherapy. Dosimetric constraint of V75 of PBT ≤ 11.9% may be used to limit clinical 
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FIGURE LEGENDS  
Figure 1. Combined Dose-Volume Histograms (DVHs) of proximal bronchial tree (A) and 
proximal bronchial tree wall (B) for 100 patients. 
Figure 2. Dose-Volume Histograms (DVHs) atlas plots for (A) Grade 1+ and (B) Grade 2+ 
PBT toxicity. 
Figure 3. Receiver operating characteristic (ROC) analysis of Dose-Volume Histograms 
(DVHs) parameters for PBT toxicity Grade 1+ (A, C) and Grade 2+ (B, D). 
Figure 4. Kaplan-Meier cumulative incidence plots for Grade 1+ (A) and Grade 2+ (B) PBT 
toxicity with optimal cutoff values of V75 of PBT. 





PBT Grade 1+  PBT Grade 2+ 
n (%) P* HR (95% CI)  n (%) P* HR (95% CI) 
Age (years)   0.217    0.719  
      ≤66  50 (50) 8 (16)  1.00 (ref.)  4 (8)  1.00 (ref.) 
      >66 50 (50) 9 (18)  1.03 (0.98-1.08)  5 (10)  1.01 (0.95-1.08) 
Gender   0.763    0.369  
      Male  82 (82) 13 (16)  1.00  6 (7)  1.00 (ref.) 
      Female 18 (18)  4 (22)  0.92 (0.52-1.61)   3 (17)  0.73 (0.36-1.46) 
Smoking   0.753    0.661  
      No 4 (4)  1 (25)  1.00 (ref.)   0 (0)  - 
      Yes 96 (96) 16 (17)  0.72 (0.10-5.47)  9 (9)  - 
Tumor location         
     Right upper lobe 45 (45) 7 (16)  1.00 (ref.)  4 (9)  1.00 (ref.) 
     Right lower lobe 16 (16)  4 (25) 0.472 0.76 (0.36-1.60)   2 (13) 0.718 0.83 (0.30-2.29) 
     Left upper lobe 28 (28) 4 (14) 0.703 1.18 (0.50-2.83)  1 (4) 0.800 1.17 (0.34-4.00) 
     Left lower lobe 11 (11) 2 (18) 0.557 0.77 (0.32-1.84)  2 (18) 0.230 0.38 (0.08-1.84) 
Tumor-PBT relationship#         
     I 39 (39) 6 (15)  1.00 (ref.)  3 (8)  1.00 (ref.) 
     II 23 (23) 4 (17) 0.698 1.29 (0.36-4.58)  1 (4) 0.669 0.61 (0.06-5.87) 
     III 24 (24) 4 (17) 0.801 1.18 (0.33-4.17)  3 (13) 0.468 1.81 (0.37-8.98) 
     IV 14 (14) 3 (21) 0.472 1.66 (0.42-6.66)  2 (14) 0.394 2.18 (0.36-13.05) 
Histology         
     Adenocarcinoma 25 (25) 5 (20)  1.00 (ref.)  3 (12)  1.00 (ref.) 
     Squamous cell 32 (32) 6 (19) 0.854 1.12 (0.34-3.67)  4 (13) 0.966 7.35 (-) 
     NOS 43 (43) 6 (14) 0.631 0.75 (0.23-2.45)  2 (5) 0.970 0.005 (-) 
Clinical stage         
     I 9 (9)  1 (11)  1.00 (ref.)   0 (0)  - 
     II 8 (8)  0 (0) 0.983 0 (0)    0 (0) - - 
     III 83 (83) 16 (19) 0.356 2.60 (0.34-19.84)  9 (11) 0.483 - 
KPS   0.168    0.782  
      ≤80 13 (13)  3 (23)  1.00 (ref.)  1 (8)  1.00 (ref.) 
      >80 87 (87) 14 (16)  0.41 (0.12-1.45)  8 (9)  0.75 (0.09-6.02) 
COPD   0.271    0.742  
      No 56 (56)  6 (11)  1.00 (ref.)  4 (7)  1.00 (ref.) 
      Yes 44 (44) 11 (25)  1.75 (0.65-4.75)  5 (11)  0.90 (0.46-1.73) 
EQD2 (Gy)   0.600    0.322  
      <70  51 (51)  7 (14)  1.00 (ref.)   3 (6)  1.00 (ref.) 
      ≥70  49 (49) 10 (20)  1.01 (0.97-1.06)  6 (12)  1.03 (0.97-1.10) 
Chemotherapy   0.431    0.472  
      No 12 (12) 1 (8)  1.00 (ref.)  0 (0)  - 
      Yes 88 (88) 16 (18)  2.25 (0.30-16.98)  9 (10)  - 
Abbreviations: PBT, proximal bronchial tree; COPD, chronic obstructive pulmonary disease; EQD2, the 2 Gy-per-fraction 
equivalent dose; KPS, Karnofsky performance status; NOS, non-otherwise specified.  
#Tumor-PBT relationship: I, the tumor is out of main bronchus; II, the tumor is within main, but >2cm to carina; III, the tumor is 
within main, and <2m to carina but not involve; IV, the tumor involves carina. 
*P values were assessed by Cox hazard univariate analysis. Age, KPS and EQD2 were analyzed as continuous variables. 
 
Table 2 Significant DVH parameters correlate PBT toxicity. 
DVH 
parameters 
Mean HR* 95% CI P* AUC 
PBT Grade 1+ Grade 0 (N=83) Grade ≥ 1 (N=17)     
V75_PBT 7.8 17.9 1.03 1.00-1.05 0.035 0.657 
V75_PBTW 9.3 18.8 1.03 1.00-1.05 0.047 0.642 
V80_PBTW 4.3 12.4 1.03 1.00-1.06 0.035 0.684 
V85_PBTW 1.9  7.6 1.04 1.00-1.08 0.032 0.651 
V95_PBTW2.5 3.4  9.7 1.04 1.00-1.07 0.033 0.639 
V100_PBTW2.5 1.6  5.8 1.05 1.00-1.09 0.029 0.602 
PBT Grade 2+ Grade 0-1 (N=91) Grade ≥ 2 (N=9)     
V75_PBT 8.4 21.3 1.04 1.00-1.07 0.037 0.729 
V75_PBTW 9.7 23.3 1.04 1.00-1.07 0.030 0.719 
V80_PBT2.5 10.3 26.4 1.03 1.00-1.06 0.043 0.723 
V75_PBTW2.5 15.8 33.6 1.03 1.00-1.06 0.048 0.697 
V80_PBTW2.5 10.9 27.0 1.03 1.00-1.06 0.044 0.724 
Abbreviations:  PBT, proximal bronchial tree; DVH, dose-volume histogram; AUC, The areas under the receiver 
operating characteristic (ROC) curves. 
*From Cox proportional hazards univariate analysis, DVH parameters were analyzed as continuous variables. 
  
Figure 1. Combined Dose-Volume Histograms (DVHs) of proximal bronchial tree (A) and 







Grade 0 (n=83) 
Grade 1 (n = 8) 
Grade 2+ (n = 9) 
Median DVH (dash) 
Grade 0 (n=83) 
Grade 1 (n = 8) 






Figure 2. Dose-Volume Histograms (DVHs) atlas plots for (A) Grade 1+ and (B) Grade 2+ proximal bronchial tree (PBT) toxicity. 
The number in percentage in each cell presents the percentile of patients with PBT toxicity within the patients whose DVH 
















Figure 3. Receiver operating characteristic (ROC) analysis of Dose-Volume Histograms (DVHs) parameters for proximal bronchial tree (PBT) toxicity Grade 1+ (A, C) and Grade 2+ (B, D). 
 








PBT, proximal bronchial tree; V75, volumes receiving doses greater than 75 Gy. 
 
Figure 4. Kaplan-Meier cumulative incidence plots for Grade 1+ (A) and Grade 2+ (B) PBT toxicity with optimal cutoff values of V75 of PBT. 
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